Du är här

2015-08-27

Actelion Pharmaceuticals Ltd: Additional data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Society of Cardiology (ESC) Congress

Actelion Pharmaceuticals Ltd / Additional data on selexipag (Uptravi) and
macitentan (Opsumit) to be presentedat European Society of Cardiology (ESC)
Congress 2015 . Processed and transmitted by NASDAQ OMX Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
ALLSCHWIL, SWITZERLAND - 27 August 2015 -
Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase
III GRIPHON study with the investigational drug selexipag (Uptravi®) will be
shared during a 'best poster session' at the European Society of Cardiology
(ESC) Congress in London, UK.

The poster presentation, titled 'Effect of selexipag on long-term outcomes in
patients with pulmonary arterial hypertension (PAH) receiving one, two or no
PAH therapies at baseline: results from the GRIPHON study' will be part of
the 'Best posters in pulmonary hypertension treatment strategies' session
with a focussed discussion with the lead author, Prof Dr Irene Lang from the
Medical University of Vienna, Vienna, Austria, at 15.30 on 30 August. The
abstract can be foundonline.

The ESC Congress will also see the presentation of further information on
macitentan (Opsumit®), with a poster titled 'Lack of pharmacokinetic
interaction between the dual endothelin receptor antagonist macitentan and
the combined oral contraceptive, norethisterone and ethinyl estradiol'. The
poster will be available for viewing from 14:00 on 30 August. The abstract
can be foundonline.

###

Notes to Editor:

SELEXIPAG AT ESC-15

Best Poster Presentation:
Effect of
selexipag on long-term outcomes in patients with pulmonary arterial
hypertension (PAH) receiving one, two or no PAH therapies at baseline:
results from the GRIPHON study [P2365]

I.M. Lang.S. Gaine, N. Galiè, H.-A.Ghofrani, F.-O Le Brun, V. McLaughlin, L.J.
Rubin, G. Simonneau, O. Sitbon, M.M. Hoeper on behalf of the GRIPHON
Steering Committee. Sunday, August 30, 15:30 - 16:30

MACITENTAN AT ESC-15

Poster presentation:
Lack of pharmacokinetic interaction between the dual endothelin receptor
antagonist macitentan and the combined oral contraceptive, norethisterone and
ethinyl estradiol
[P2645]

N. Hurst.Sunday, August 30, 14:00 - 18:00

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides type
cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia
and Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of
the company's investment and research and development programs and
anticipated expenditures in connection therewith, descriptions of new
products expected to be introduced by the company and anticipated customer
demand for such products and products in the company's existing portfolio.
Such statements reflect the current views of the company with respect to
future events and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future
results, performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those described herein as
anticipated, believed, estimated or expected.

Press Release PDF
http://hugin.info/131801/R/1947752/707301.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1947752

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.